論文 - 詳細
| RRC ID | 57844 |
|---|---|
| 著者 | Hirata-Nozaki Y, Ohkuri T, Ohara K, Kumai T, Nagata M, Harabuchi S, Kosaka A, Nagato T, Ishibashi K, Oikawa K, Aoki N, Ohara M, Harabuchi Y, Uno Y, Takei H, Celis E, Kobayashi H. |
| タイトル | PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. |
| ジャーナル | J Transl Med |
| Abstract |
BACKGROUND:Head and neck squamous cell carcinoma (HNSCC) originates from squamous epithelium of the upper aerodigestive tract and is the most common malignancy in the head and neck region. Among HNSCCs, oropharynx squamous cell carcinoma (OSCC) has a unique profile and is associated with human papillomavirus infection. Recently, anti-programmed cell death-1 monoclonal antibody has yielded good clinical responses in recurrent and/or metastatic HNSCC patients. Therefore, programmed death-ligand 1 (PD-L1) may be a favorable target molecule for cancer immunotherapy. Although PD-L1-expressing malignant cells could be targeted by PD-L1-specific CD8+ cytotoxic T lymphocytes, it remains unclear whether CD4+ helper T lymphocytes (HTLs) recognize and kill tumor cells in a PD-L1-specific manner. METHODS:The expression levels of PD-L1 and HLA-DR were evaluated using immunohistochemical analyses. MHC class II-binding peptides for PD-L1 were designed based on computer algorithm analyses and added into in vitro culture of HTLs with antigen-presenting cells to evaluate their stimulatory activity. RESULTS:We found that seven of 24 cases of OSCC showed positive for both PD-L1 and HLA-DR and that PD-L1241-265 peptide efficiently activates HTLs, which showed not only cytokine production but also cytotoxicity against tumor cells in a PD-L1-dependent manner. Also, an adoptive transfer of the PD-L1-specific HTLs significantly inhibited growth of PD-L1-expressing human tumor cell lines in an immunodeficient mouse model. Importantly, T cell responses specific for the PD-L1241-265 peptide were detected in the HNSCC patients. CONCLUSIONS:The cancer immunotherapy targeting PD-L1 as a helper T-cell antigen would be a rational strategy for HNSCC patients. |
| 巻・号 | 17(1) |
| ページ | 207 |
| 公開日 | 2019-6-20 |
| DOI | 10.1186/s12967-019-1957-5 |
| PII | 10.1186/s12967-019-1957-5 |
| PMID | 31221178 |
| PMC | PMC6585001 |
| MeSH | Animals B7-H1 Antigen / antagonists & inhibitors B7-H1 Antigen / genetics B7-H1 Antigen / metabolism* Cell Line, Tumor Cells, Cultured Cytotoxicity, Immunologic / genetics Cytotoxicity, Immunologic / immunology Epitopes, T-Lymphocyte / chemistry Epitopes, T-Lymphocyte / therapeutic use Female Gene Knockdown Techniques Head and Neck Neoplasms / immunology* Head and Neck Neoplasms / pathology Head and Neck Neoplasms / therapy* Humans Immunotherapy / methods* Immunotherapy / trends Lymphocytes, Tumor-Infiltrating / immunology Lymphocytes, Tumor-Infiltrating / metabolism Mice Mice, Inbred BALB C Mice, Nude Peptide Fragments / immunology Peptide Fragments / therapeutic use Squamous Cell Carcinoma of Head and Neck / immunology* Squamous Cell Carcinoma of Head and Neck / metabolism Squamous Cell Carcinoma of Head and Neck / therapy* T-Lymphocytes, Helper-Inducer / metabolism T-Lymphocytes, Helper-Inducer / physiology* |
| IF | 4.124 |
| 引用数 | 2 |
| リソース情報 | |
| ヒト・動物細胞 | LU65(RCB1967) |